Skip Navigation


Rheumatology Advance Access originally published online on November 15, 2005
Rheumatology 2006 45(3):325-331; doi:10.1093/rheumatology/kei157
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
45/3/325    most recent
kei157v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hallert, E.
Right arrow Articles by Skogh, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hallert, E.
Right arrow Articles by Skogh, T.
Related Collections
Right arrow Rheumatoid Arthritis
Right arrow Health Economics
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Published by Oxford University Press 2005.

Costs and course of disease and function in early rheumatoid arthritis: a 3-year follow-up (the Swedish TIRA project)

E. Hallert1,2, M. Husberg2 and T. Skogh1

1 Division of Rheumatology/AIR, Department of Molecular and Clinical Medicine, Faculty of Health Sciences, Linköping University Hospital and 2 Centre for Medical Technology Assessment, Department of Health and Society, Linköping University, Linköping, Sweden.

Correspondence to: T. Skogh, Division of Rheumatology/AIR, Department of Molecular and Clinical Medicine, Linköping University Hospital, SE-581 85 Linköping, Sweden. E-mail: thomas.skogh{at}lio.se

Objective. To calculate direct and indirect costs and to study disease activity and functional ability over 3 yr in early rheumatoid arthritis (RA).

Methods. Three hundred and three patients with early (≤1 yr) RA were recruited during a period of 27 months (1996–1998). Data were recorded during 3 yr to assess disease activity, functional ability, medication, health-care utilization and days lost from work.

Results. Within 3 months, improvements were seen regarding all recorded variables assessing disease activity and functional ability, but 15% had sustained high or moderate disease activity throughout the study period. Indirect costs exceeded direct costs in all 3 yr. The average direct costs were {euro} 3704 (US$ 3297) in year 1 and {euro} 2652 (US$ 2360) in year 3. All costs decreased, except those for medication and surgery. Compared with men, women had more ambulatory care visits and used more complementary medicine. The indirect costs were {euro} 8871 (US$ 7895) in year 1 and remained essentially unchanged; this was similar for both sexes. Almost 50% were on sick leave or early retirement at inclusion. Sick leave decreased but was offset by an increase in early retirement. The 14 patients who eventually received TNF inhibitors incurred higher costs even before prescription of anti-TNF therapy.

Conclusion. Disease activity and functional ability improved within 3 months after diagnosis of early RA. Direct costs decreased, except for medication and surgery. Indirect costs remained unchanged. Fifteen per cent of the patients had high or moderate disease activity in all 3 yr, indicating a need for more aggressive early anti-rheumatic therapy.

KEY WORDS: Rheumatoid arthritis, Costs, Disease course


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Rheumatology (Oxford)Home page
S. M. M. Verstappen, J. W. G. Jacobs, A. A. Kruize, J. C. Ehrlich, G. A. van Albada-Kuipers, H. Verkleij, E. Buskens, and J. W. J. Bijlsma
Trends in economic consequences of rheumatoid arthritis over two subsequent years
Rheumatology, June 1, 2007; 46(6): 968 - 974.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
R. Callaghan, A. Prabu, R. B. Allan, A. E. Clarke, N. Sutcliffe, Y. St. Pierre, C. Gordon, S. J. Bowman, and the UK Sjogren's Interest Group
Direct healthcare costs and predictors of costs in patients with primary Sjogren's syndrome
Rheumatology, January 1, 2007; 46(1): 105 - 111.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.